Onconova Therapeutics (NASDAQ ONTX at https://www.webull.com/newslist/nasdaq-ontx) was updated by values specialists at Noble Financial from a “market perform” rating to a “beat” rating in an examination report gave to customers and speculators on Tuesday, Benzinga reports.
Various other examination investigators have likewise as of late remarked on ONTX. Zacks Investment Research cut portions of Onconova Therapeutics from a “purchase” rating to a “hold” rating in a report on Saturday, October tenth. HC Wainwright cut portions of Onconova Therapeutics from a “purchase” rating to an “impartial” rating in a report on Monday, August 24th. Laidlaw cut portions of Onconova Therapeutics from a “purchase” rating to a “hold” rating in a report on Monday, August 24th. At long last, Maxim Group reissued a “hold” rating on portions of Onconova Therapeutics in a report on Friday, November thirteenth. Four speculation examiners have evaluated the stock with a hold rating and two have given a purchase rating to the stock. The stock has an agreement rating of “Hold” and an agreement value focus of $1.20.
Onconova Therapeutics stock exchanged up $0.05 during exchanging hours on Tuesday, coming to $0.41. 390,710 portions of the stock were traded, contrasted with its normal volume of 15,371,232. The organization has a market cap of $76.46 million, a P/E proportion of – 0.28, and a beta of 1.93. Onconova Therapeutics has a year low of $0.19 and a year high of $1.56. The stock has a multi-day moving normal of $0.29 and a multi-day moving normal of $0.49.
Onconova Therapeutics (NASDAQ ONTX) last posted its profit results on Thursday, November twelfth. The biopharmaceutical organization revealed ($0.03) EPS for the quarter, missing examiners’ agreement evaluations of ($0.02) by ($0.01). The organization had an income of $0.07 million during the quarter, contrasted with the agreement gauge of $4.10 million. Onconova Therapeutics had a negative profit for a value of 214.79% and a negative net edge of 11,357.71%. By and large, sell-side investigators foresee that Onconova Therapeutics will post – 0.12 income per share for the current year.
Various mutual funds and other institutional financial specialists have as of late adjusted their property of the stock. Jane Street Group LLC purchased another situation in Onconova Therapeutics in the second quarter esteemed at around $28,000. Captrust Financial Advisors purchased another situation in Onconova Therapeutics in the second quarter esteemed at roughly $59,000. Quilter Plc brought its property up in Onconova Therapeutics by 78.4% in the third quarter. Quilter Plc presently claims 284,750 portions of the biopharmaceutical organization’s stock esteemed at $80,000 in the wake of purchasing an extra 125,117 offers during the last quarter. Squarepoint Ops LLC brought its property up in Onconova Therapeutics by 3,020.1% in the third quarter. Squarepoint Ops LLC presently possesses 331,039 portions of the biopharmaceutical organization’s stock esteemed at $93,000 in the wake of purchasing an extra 320,429 offers during the last quarter. At long last, Perkins Capital Management Inc. purchased another situation in Onconova Therapeutics in the third quarter esteemed at around $105,000. Institutional financial specialists and multifaceted investments own 5.87% of the organization’s stock. Before investing in stocks, you can check other stocks information like nyse agcb at https://www.webull.com/quote/nyse-agcb.